SEC Form 4 · accession 0001193125-26-388156
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lorence H. Kim
Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 5:52 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F4 | Sep 8, 2026 | S | 706 | $206.6049 | D | 16,384 | I | Trust |
| Common StockF5,F4 | Sep 8, 2026 | S | 999 | $207.3321 | D | 15,385 | I | Trust |
| Common StockF6,F4 | Sep 8, 2026 | S | 3,587 | $208.5534 | D | 11,798 | I | Trust |
| Common StockF7,F4 | Sep 8, 2026 | S | 2,853 | $209.56 | D | 8,945 | I | Trust |
| Common StockF8,F4 | Sep 8, 2026 | S | 4,730 | $210.5028 | D | 4,215 | I | Trust |
| Common StockF9,F4 | Sep 8, 2026 | S | 3,844 | $211.3588 | D | 371 | I | Trust |
| Common StockF10,F4 | Sep 8, 2026 | S | 371 | $212.2693 | D | 0 | I | Trust |
| Common StockF1 | holding | — | — | — | 1,191 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 1,191 restricted stock units.
- F10The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F2Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
- F3The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4Shares held by the Lorence Kim Revocable Trust.
- F5The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.